1932

Abstract

Treatment for opioid use disorder in the United States evolved in response to changing federal policy and advances in science. Inpatient care began in 1935 with the US Public Health Service Hospitals in Lexington, Kentucky, and Fort Worth, Texas. Outpatient clinics emerged in the 1960s to provide aftercare. Research advances led to opioid agonist and opioid antagonist therapies. When patients complete opioid withdrawal, return to use is often rapid and frequently deadly. US and international authorities recommend opioid agonist therapy (i.e., methadone or buprenorphine). Opioid antagonist therapy (i.e., extended-release naltrexone) may also inhibit return to use. Prevention efforts emphasize public and prescriber education, use of prescription drug monitoring programs, and safe medication disposal options. Overdose education and naloxone distribution promote access to rescue medication and reduce opioid overdose fatalities. Opioid use disorder prevention and treatment must embrace evidence-based care and integrate with physical and mental health care.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-publhealth-040617-013526
2018-04-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/publhealth/39/1/annurev-publhealth-040617-013526.html?itemId=/content/journals/10.1146/annurev-publhealth-040617-013526&mimeType=html&fmt=ahah

Literature Cited

  1. Abraham AJ, Andrews CM, Grogan CM, D'Aunno T, Humphreys KN. 1.  et al. 2017. The Affordable Care Act transformation of substance use disorder treatment. Am. J. Public Health 107:31–32 [Google Scholar]
  2. Alanis-Hirsch K, Croff R, Ford JH 2nd, Johnson K, Chalk M. 2.  et al. 2016. Extended-release naltrexone: a qualitative analysis of barriers to routine use. J. Subst. Abuse Treat 62:68–73 [Google Scholar]
  3. Albert S, Brawon FW 2nd, Sanford CK, Dasgupta N, Graham J, Lovette B. 3.  2011. Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med 12:S77–85 [Google Scholar]
  4. Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M. 4.  et al. 2011. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch. Intern. Med. 171:425–31 [Google Scholar]
  5. 5. ASAM (Am. Soc. Addict. Med.). 2013. The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions D Mee-Lee Washington, DC: ASAM
  6. Barry CL, Huskamp HA. 6.  2011. Moving beyond parity—mental health and addiction care under the ACA. N. Engl. J. Med. 365:973–75 [Google Scholar]
  7. Berridge V. 7.  2009. Heroin prescription and history. N. Engl. J. Med. 361:820–21 [Google Scholar]
  8. Besteman KJ. 8.  1992. Federal leadership in building the national drug treatment system. Treating Drug Problems: Volume 2 DR Gerstein, HJ Harwood 63–88 Washington, DC: Natl. Acad. Press [Google Scholar]
  9. Brooklyn JR, Sigmon SC. 9.  2017. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict. Med. 11:286–92 [Google Scholar]
  10. Buck JA. 10.  2011. The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Aff 30:1402–10 [Google Scholar]
  11. Campbell ND, Olsen JP, Walden L. 11.  2008. The Narcotic Farm: The Rise and Fall of America's First Prison for Drug Addicts New York: Abrams
  12. 12. CDC (Cent. Dis. Control Prev.) Health Advis. 2015. Increases in fentanyl drug confiscations and fentanyl-related overdose fatalities CDCHAN-00384, Oct. 26, CDC Health Alert Netw Atlanta: https://emergency.cdc.gov/han/han00384.asp
  13. 13. CMS (Cent. Medicare Medicaid Serv.). 2016. Medicaid and CHIP managed care final rule. Fed. Regist. 81:27498–901 https://www.medicaid.gov/medicaid/managed-care/guidance/final-rule/index.html [Google Scholar]
  14. Courtwright D, Joseph H, Des Jarlais D. 14.  1989. Addicts Who Survived: An Oral History of Narcotic Use in America, 19231965 Knoxville: Univ. Tenn. Press [Google Scholar]
  15. Courtwright DT. 15.  1982. Dark Paradise: Opiate Addiction in America Before 1940 Cambridge, MA: Harvard Univ. Press
  16. De Leon G, Rosenthal MS. 16.  1979. Therapeutic communities. See Ref. 25 39–47
  17. DeBeck K, Kerr T, Bird L, Zhang R, Marsh DC. 17.  et al. 2011. Injection drug use cessation and use of North America's first medically supervised safer injecting facility. Drug Alcohol Depend 113:172–76 [Google Scholar]
  18. Deyo RA, Irvine JM, Millet LM, Beran T, O'Kane N. 18.  et al. 2013. Measures such as interstate cooperation would improve the efficacy of programs to track controlled drug prescriptions. Health Aff 32:603–13 [Google Scholar]
  19. 19. Divers. Control Div. 2017. Controlled substance schedules US Dep. Justice, Drug Enforc. Adm Springfield, VA: https://www.deadiversion.usdoj.gov/schedules/
  20. Dole VP, Nyswander M. 20.  1965. A medical treatment of diacetylmorphine (heroin) addiction: a clinic trial with methadone hydrochloride. JAMA 193:646–50 [Google Scholar]
  21. Dole VP, Nyswander ME, Kreek MJ. 21.  1966. Narcotic blockade. Arch. Intern. Med. 118:304–9 [Google Scholar]
  22. Dowell D, Haegerich TM, Chou R. 22.  2016. CDC guideline for prescribing opioids for chronic pain—United States, 2016.. JAMA 315:1624–45 [Google Scholar]
  23. Dowell D, Haegerich TM, Chou R. 23.  2016. CDC guideline for prescribing opioids for chronic pain—United States, 2016.. MMWR 65:1–49 [Google Scholar]
  24. 24. Drug Enforc. Adm. Off. Divers. Control. 2006. Practitioner's Manual: An Informational Outline of the Controlled Substances Act Washington, DC: Drug Enforc. Adm https://www.deadiversion.usdoj.gov/pubs/manuals/pract/pract_manual012508.pdf
  25. Dupont RI, Goldstein A, O'Donnell J. 25.  1979. Handbook on Drug Abuse Washington, DC: Natl. Inst. Drug Abuse
  26. Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV. 26.  et al. 2008. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am. J. Addict. 17:116–20 [Google Scholar]
  27. Fiellin DA, O'Conner PG. 27.  2002. Office-based treatment of opioid-dependent patients. N. Engl. J. Med. 347:817–23 [Google Scholar]
  28. Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE. 28.  2006. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N. Engl. J. Med. 355:365–74 [Google Scholar]
  29. Fiellin DA, Pantalon MV, Pakes JP, O'Conner PG, Chawarski MC, Schottenfeld RS. 29.  2002. Treatment of heroin dependence with buprenorphine in primary care. Am. J. Drug Alcohol Abuse 28:231–41 [Google Scholar]
  30. Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL. 30.  et al. 2011. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J. Acquir. Immune Defic. Syndr. 56:33–38 [Google Scholar]
  31. Friedmann PD, Andrews CM, Humphreys K. 31.  2017. How ACA repeal would worsen the opioid epidemic. N. Engl. J. Med. 376:e16 [Google Scholar]
  32. Gastfriend DR. 32.  2011. Intramuscular extended-release naltrexone: current evidence. Ann. N. Y. Acad. Sci. 1216:144–66 [Google Scholar]
  33. Gourevitch MN, Arnsten J. 33.  2005. Medical complications of drug use. Substance Abuse: A Comprehensive Textbook JH Lowinson, P Ruiz, RB Millman, JG Langrod 840–67 Philadelphia: Lippincott Williams & Wilkins, 4th ed.. [Google Scholar]
  34. Gupta R, Shah ND, Ross JS. 34.  2016. The rising price of naloxone—risks to efforts to stem overdose deaths. N. Engl. J. Med. 375:2213–15 [Google Scholar]
  35. Hser YI, Hoffman V, Grella CE, Anglin MD. 35.  2001. A 33-year follow-up of narcotic addicts. Arch. Gen. Psychiatry 58:503–8 [Google Scholar]
  36. Hughes A, Williams MR, Lipari RN, Bose J, Copello EAP, Kroutil LA. 36.  2016. Prescription drug use and misuse in the United States: results from the 2015 National Survey on Drug Use and Health Sept., NSDUH Data Rev., Substance Abuse and Mental Health Services Administration Rockville, MD: https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm
  37. 37. Inst. Med. 1990. Treating Drug Problems 1 A Study of the Evolution, Effectiveness, and Financing of Public and Private Drug Treatment Systems DR Gerstein, HJ Harwood Washington, DC: Natl. Acad. Press
  38. 38. Inst. Med. 1995. Federal Regulation of Methadone Treatment RA Retting, A Yarmolinsky Washington, DC: Natl. Acad. Press
  39. 39. Inst. Med. 1997. Managing Managed Care: Quality Improvement in Behavioral Health M Edmunds, R Frank, M Hogan, D McCarty, R Robinson-Beale, C Weisner Washington, DC: Natl. Acad. Press
  40. Jaffe JH. 40.  1997. The history and current status of opiate agonist treatment. NIH Consens. Dev. Conf. Statement: Effective Medical Treatment of Heroin Addiction Nov 17–1919–25 Bethesda, MD: Natl. Inst. Health [Google Scholar]
  41. Jaffe JH, O'Keeffe C. 41.  2003. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 70:S3–11 [Google Scholar]
  42. Jasinski DR, Pevnick JS, Griffith JD. 42.  1978. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch. Gen. Psychiatry 35:501–16 [Google Scholar]
  43. Joseph H, Stancliff S, Langrod J. 43.  2000. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J. Med. 67:347–64 [Google Scholar]
  44. Julius D. 44.  1976. NIDA's naltrexone research program. Narcotic Antagonists: Naltrexone. Progress Report D Julius, P Renault 5–11 NIDA Res. Monogr. 9 Washington, DC: Alcohol, Drug Abuse Mental Health Adm. [Google Scholar]
  45. Kampman K, Jarvis M. 45.  2015. American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. J. Addict. Med. 9:358–67 [Google Scholar]
  46. Kerensky T, Walley AY. 46.  2017. Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know. Addict. Sci. Clin. Pract. 12:4 [Google Scholar]
  47. Kerr T, Montaner JSG, Wood E. 47.  2010. Science and politics of heroin prescription. Lancet 375:1849–50 [Google Scholar]
  48. Kerr T, Tyndall MW, Li K, Montaner J, Wood E. 48.  2005. Safer injection facility use and syringe sharing in injection drug users. Lancet 366:316–18 [Google Scholar]
  49. Knudsen HK, Abraham AJ, Oser CB. 49.  2011. Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure. Eval. Prog. Plan. 34:375–81 [Google Scholar]
  50. Knudsen HK, Abraham AJ, Roman PM. 50.  2011. Adoption and implementation of medications in addiction treatment programs. J. Addict. Med. 5:21–27 [Google Scholar]
  51. Knudsen HK, Roman PM. 51.  2012. Financial factors and the implementation of medications for treating opioid use disorders. J. Addict. Med. 6:280–86 [Google Scholar]
  52. Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL. 52.  et al. 2015. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu. Rev. Public Health 36:559–74 [Google Scholar]
  53. Komaromy M, Duhigg D, Metcalf A, Carlson C, Kalishman S. 53.  et al. 2016. Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst. Abuse 37:20–24 [Google Scholar]
  54. Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I. 54.  et al. 2017. Primary care-based models for the treatment of opioid use disorder: a scoping review. Ann. Intern. Med. 166:268–78 [Google Scholar]
  55. Kreek MJ, Vocci FJ. 55.  2002. History and current status of opioid maintenance treatments. J. Subst. Abuse Treat 23:93–105 [Google Scholar]
  56. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. 56.  2011. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicenter randomised trial. Lancet 377:1506–13 [Google Scholar]
  57. LaBelle CT, Han SC, Bergeron A, Samet JH. 57.  2016. Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts collaborative care model in community health centers. J. Subst. Abuse Treat. 60:6–13 [Google Scholar]
  58. Legisetty P. 58.  2017. The fine line between doctoring and dealing. Health Aff 36:186–89 [Google Scholar]
  59. Leukefeld CG. 59.  1991. Opportunities for enhancing drug abuse treatment with criminal justice authority. Improving Drug Abuse Treatment RW Pickens, CG Leukefeld, CR Schuster 328–37 Res. Monogr. 106 Rockville, MD: Natl. Inst. Drug Abuse [Google Scholar]
  60. Maddux JF. 60.  1988. Clinical experience with civil commitment. Compulsory Treatment of Drug Abuse: Research and Clinical Practice CG Leukefeld, FM Tims 35–56 NIDA Res. Monogr. 86 Washington, DC: Gov. Print. Off. [Google Scholar]
  61. Marshall BDL, Milloy M-J, Wood E, Montaner JSG, Kerr T. 61.  2011. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet 377:1429–37 [Google Scholar]
  62. McCarty D, Bovett R, Burns T, Cushing J, Glynn ME. 62.  et al. 2015. Oregon's strategy to confront prescription opioid misuse: a case study. J. Subst. Abuse Treat. 48:91–95 [Google Scholar]
  63. 63. Minist. Health. 1926. Rolleston Report: Departmental Committee on Morphine and Heroin Addiction London: Minist. Health
  64. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. 64.  2011. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst. Rev.4CD001333 [Google Scholar]
  65. Murthy VH. 65.  2016. Ending the opioid epidemic—a call to action. N. Engl. J. Med. 375:2413–15 [Google Scholar]
  66. Musto DF. 66.  1973. The American Disease: Origins of Narcotic Control New Haven, CT: Yale Univ. Press
  67. Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S. 67.  et al. 2012. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. Can. Med. Assoc. J. 184:E317–28 [Google Scholar]
  68. 68. Off. Assist. Secr. Plan. Eval. 2015. Opioid abuse in the U.S. and HHS actions to address opioid-drug related overdoses and deaths. ASPE Issue Brief, March 26. Dep. Health Hum. Serv Washington, DC: https://aspe.hhs.gov/basic-report/opioid-abuse-us-and-hhs-actions-address-opioid-drug-related-overdoses-and-deaths
  69. 69. Off. Mo. Gov. Eric Greitens. 2017. Governor Eric Greitens announces statewide prescription drug monitoring program News Release, July 17. https://governor.mo.gov/news/archive/governor-eric-greitens-announces-statewide-prescription-drug-monitoring-program
  70. 70. Off. Natl. Drug Control Policy. 2011. Epidemic: Responding to America's Prescription Drug Abuse Crisis Washington, DC: Exec. Off. Pres. US https://obamawhitehouse.archives.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf
  71. 71. Off. Surg. Gen. 2016. Facing Addiction in America: The Surgeon General's Report on Alcohol Drugs and Health Washington, DC: US Dep. Health Hum. Serv https://addiction.surgeongeneral.gov/surgeon-generals-report.pdf
  72. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D. 72.  et al. 2009. Diacetylmorphine versus methadone for the treatment of opioid addiction. N. Engl. J. Med. 361:777–86 [Google Scholar]
  73. Peterson AB, Gladden RM, Delcher C, Spies E, Garcia-Williams A. 73.  et al. 2016. Increases in fentanyl-related overdose deaths—Florida and Ohio 2013–2015. MMWR 65:844–49 [Google Scholar]
  74. Phillips KA, Friedmann PD, Saitz R, Samet JH. 74.  2014. Linking addiction treatment with other medical and psychiatric treatment systems. See Ref. 79 442–55
  75. 75. Proj. Lazarus. 2017. The Project Lazarus model Proj. Lazarus, Moravian Falls, NC. https://www.projectlazarus.org/the-model
  76. 76. Prov. Opioid Use Disord. Treat. Guidel. Comm. 2017. A Guideline for the Clinical Management of Opioid Use Disorder Vancouver, Can.: B. C. Cent. Subst. Use http://www.bccsu.ca/wp-content/uploads/2017/06/BC-OUD-Guidelines_June2017.pdf
  77. Resnick RB, Schuyten-Resnick E, Washton AM. 77.  1979. Treatment of opioid dependence with narcotic antagonists. See Ref. 25, pp. 97–104
  78. Rieder TN. 78.  2017. In opioid withdrawal, with no help in sight. Health Aff 36:182–85 [Google Scholar]
  79. Ries RK, Fiellin DA, Miller SC, Saitz R. 79.  2014. The ASAM Principles of Addiction Medicine Philadelphia: Wolters Kluwer, 5th ed..
  80. Rudd RA, Seth P, David F, Scholl L. 80.  2016. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR 65:1445–52 [Google Scholar]
  81. Saitz R. 81.  2014. Medical and surgical complications of addiction. See Ref. 79 1067–89
  82. 82. SAMHSA (Subst. Abuse Mental Health Serv. Adm.). 2017. National Survey of Substance Abuse Treatment Services (N-SSATS): 2016. Data on Substance Abuse Treatment Facilities. Rockville, MD: SAMHSA https://wwwdasis.samhsa.gov/dasis2/nssats/2016_nssats_rpt.pdf
  83. 83. SAMHSA (Subst. Abuse Mental Health Serv. Adm.). 2017. Treatment Episode Data Set (TEDS): 2005–2015. National Admissions to Substance Abuse Treatment Services. Rockville, MD: SAMHSA https://www.samhsa.gov/data/sites/default/files/2015_Treatment_Episode_Data_Set_National/2015_Treatment_Episode_Data_Set_National.pdf
  84. Somerville NJ, O'Donnell J, Gladden RM, Zibbell JE, Green TC. 84.  et al. 2017. Characteristics of fentanyl overdose—Massachusetts, 2014–2016. MMWR 66:382–86 [Google Scholar]
  85. Stoller KB. 85.  2015. A collaborative opioid prescribing (CoOP) model linking opioid treatment programs with office-based buprenorphine providers. Addict. Sci. Clin. Pract. 10:Suppl. 1A63 [Google Scholar]
  86. 86. UNODC (UN Off. Drugs Crime), WHO (World Health Organ.). 2017. International Standards for the Treatment of Drug Use Disorders Vienna: UNODC https://www.unodc.org/documents/drug-prevention-and-treatment/UNODC_International_Standards_for_the_Treatment_of_Drug_Use_Disorders_March_17_ebook.pdf
  87. 87. US CMS (Cent. Medicare Medicaid Serv.). 2017. Letter to C. Beane, Oct. 6. CMS Washington, DC: https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Waivers/1115/downloads/wv/wv-creating-continuum-care-medicaid-enrollees-substance-ca.pdf
  88. 88. US Dep. HHS (Health Hum. Serv.). 2016. The Mental Health and Substance Use Disorder Parity Task Force: Final Report Washington, DC: US Dep. HHS https://www.hhs.gov/sites/default/files/mental-health-substance-use-disorder-parity-task-force-final-report.pdf
  89. Vestal C. 89.  2017. States seek Medicaid dollars for addiction treatment beds. Stateline April 5. http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2017/04/05/states-seek-medicaid-dollars-for-addiction-treatment-beds
  90. Volkow ND, Collins FS. 90.  2017. The role of science in addressing the opioid crisis. N. Engl. J. Med. 377:391–94 [Google Scholar]
  91. Wachino V. 91.  2015. Re: New service delivery opportunities for individuals with a substance use disorder SMD 15-003, July 27 Dep. Health Hum. Serv Baltimore, MD: https://www.medicaid.gov/federal-policy-guidance/downloads/smd15003.pdf
  92. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M. 92.  et al. 2013. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 346:f174 [Google Scholar]
  93. Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM. 93.  2011. Drug poisoning deaths in the United States, 1980–2008. NCHS Data Brief811–13 [Google Scholar]
  94. Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS. 94.  et al. 2011. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch. Gen. Psychiatry 68:1238–46 [Google Scholar]
  95. Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM. 95.  et al. 2015. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend 150:112–19 [Google Scholar]
  96. White W, Callahan JF. 96.  2014. Addiction medicine in America: its birth and early history (1750–1935) with a modern postscript. See Ref. 79 365–74
  97. 97. White House Off. Press Secr. 2017. President Donald J. Trump signs an Executive Order establishing the President's Commission on Combating Drug Addiction and the Opioid Crisis Press Release, March 29. https://www.whitehouse.gov/the-press-office/2017/03/30/president-donald-j-trump-signs-executive-order-establishing-presidents
  98. 98. White House Off. Press Secr. 2017. Presidential Executive Order establishing the President's Commission on Combating Drug Addiction and the Opioid Crisis News Release, March 29. https://www.whitehouse.gov/the-press-office/2017/03/30/presidential-executive-order-establishing-presidents-commission
  99. Wood E, Kerr T, Lloyd-Smith E, Buchner C, Marsh DC. 99.  et al. 2004. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduct. J. 13:95–102 [Google Scholar]
  100. Wood E, Kerr T, Small W, Li K, Marsh DC. 100.  et al. 2004. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. Can. Med. Assoc. J. 171:731–34 [Google Scholar]
/content/journals/10.1146/annurev-publhealth-040617-013526
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error